Persistent akathisia masquerading as agitated depression after use of ziprasidone in the treatment of bipolar depression

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 463-465

  Penders, Thomas M ^a   Agarwal, Salina ^b   Rohaidy, Rachel ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Affective; Antipsychotic; Extrapyramidal; Mood disorder; Second generation; Suicide

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; LITHIUM; LORAZEPAM; NEBIVOLOL; PROPRANOLOL; QUETIAPINE; SERTRALINE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

AGED; AGITATION; AKATHISIA; ANHEDONIA; ANXIETY; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR II DISORDER; CASE REPORT; COGNITIVE DEFECT; COORDINATION DISORDER; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; HOPELESSNESS; HUMAN; HYPERACTIVITY; HYPOMANIA; INSOMNIA; IRRITABILITY; LETHARGY; LOGORRHEA; ORTHOSTATIC HYPOTENSION; PHOTOTHERAPY; PSYCHOSOCIAL WITHDRAWAL; QUICK INVENTORY OF DEPRESSION SYMPTOMS SCORE; RESTLESSNESS; SCORING SYSTEM; SUICIDAL IDEATION;

EID: 84875985268     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S43113     Document Type: Article

References (16)

1. Pompili M, Gianluca S, Marco I, Unmet treatment needs in schizophrenic patients: is asenapine a potential therapeutic option? Expert Rev Neurother. 2011;11(7):989-1006.
2. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000;61 Suppl 3:16-21.
3. Hirose S. The causes of under diagnosing akathisia. Schizophr Bull. 2003;29:547-558.
4. Kumar R, Sachem PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009;22:293-299.
5. Oral ET, Altinbas K, Demirkiran S. Sudden akathisia after a ziprasidone dose reduction. Am J Psychiatry. 2006;163:546.
6. Gao K, Kemp DE, Ganocy J et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28:2039.
7. Seemüller F, Shennach AM, Mayr A, German Study Group on First-Episode Schizophrenia. Akathisia and suicidal ideation in first-episode schizophrenia. J Clin Psychopharmacol. 2012;32:694-698.
8. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assunção-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70:627-643.
9. Cohen BM, Keck PE, Satlin A, Cole JO. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry. 1991;29:1215-1219.
10. Rummel-Kluge, Kamossa K, Schwartz S, Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head to head comparisons. Schizophr Bull. 2010;38:167-177.
11. David DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasadone 80mg/day and 160mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999;20:491-505.
12. Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry. 1985;142:499-550.
13. Cem Atbaşoglu EC, Schultz SK, Andreasen NC. The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. J Neuropsychiatry Clin Neurosci. 2001;13:336-341.
14. Young AH, McElroy SL, Bauer M, EMBOLDEN I (Trial 001) Investigators. A double blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71:150-162.
15. DeFruyl J, Deschepper E, Audenaert K, ]Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012;26:603-617.
16. Moteshafi H, Stip E. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert Opin Drug Saf. 2012;11:713-732.